

a3rd international convening of

Planning for Prevention of Parkinson's: A trial design forum

May 5-7, 2024

[Boston Marriott Long Wharf](#) – Boston, MA, USA & online

AGENDA

Sunday – May 5 th			
Time	Event	Speakers	Location
1:30 - 2:30 PM	Elective excursion 1: Waterfront walking talk on 'Exercise & PD Prevention' <i>With media posting & commentary by Kathleen McKee</i> Meet outside north entrance of Boston Marriott Long Wharf	Bas Bloem	Boston Harborwalk
3:00 - 5:00 PM (Boarding begins at 2:45 PM)	Elective excursion 2: Boston Harbor boat tour and talk: Preparing for primary care and direct-to-consumer testing for PD <i>With media posting & commentary by Kathleen McKee</i> <u>Advance Registration Required</u>	Kathleen Poston	Rowes Wharf, Gate A
5:30 - 7:00 PM	Welcome Reception	In-Person Attendees Only	Harborview Ballroom & Terrace
5:30 - 7:00 PM	Poster Session	In-Person Attendees Only	Commonwealth Ballroom

Monday – May 6 th			
Time	Event	Speakers	Location
7:00 - 8:00 AM	Breakfast	All	Palm Garden
8:00 - 9:00 AM	Opening Session <ul style="list-style-type: none"> Welcome At-risk perspectives Questions from audience 	*Grace Crotty Grace Crotty Allen Dance, John Poma, Jessi Keavney	Grand Ballroom Salons ABCDEFGL
9:00 - 10:45 AM	Biologic advances impacting trial design: <ul style="list-style-type: none"> Perspective on progress αSyn-based biomarkers <ul style="list-style-type: none"> Biology assay advances Human studies update 	*Michael Schwarzschild Billy Dunn Tiago Outeiro Andrew Siderowf	

	<ul style="list-style-type: none"> Enabling prevention trials via: <ul style="list-style-type: none"> NSD staging SynNeurGe classification Panel discussion; audience Q&A 	<p>Tanya Simuni Anthony Lang Camille Carroll, Tien Dam, Anthony Lang, Tiago Outeiro, Andrew Siderowf, Tanya Simuni</p>	
10:45 - 11:00 AM	Break	All	
11:00 AM – 12:30 PM	<p>WHO?: Selecting an at-risk population</p> <ul style="list-style-type: none"> +’s & -’s, and αSyn impact for: <ul style="list-style-type: none"> Genetic cohorts RBD-based cohorts Population-based risk cohorts Panel discussion; audience Q&A 	<p>*Daniela Berg Rachel Saunders-Pullman & Deborah Raymond Ron Postuma Alberto Ascherio Alberto Ascherio, Chantale Branson, Ron Postuma, Deborah Raymond, Rachel Saunders-Pullman, Wolfgang Oertel</p>	Grand Ballroom Salons ABCDEFGL
12:30 - 1:45 PM	Lunch	All	Palm Garden
12:30 - 1:45 PM	Poster Session	In-Person Attendees Only	Commonwealth Ballroom
1:45 - 3:00 PM	<p>WHAT to test?: Selecting an intervention</p> <ul style="list-style-type: none"> Lifestyle/exercise interventions Drug candidate selection principles Panel discussion; audience Q&A 	<p>*Carlie Tanner Bas Bloem Michael Schwarzschild Bas Bloem, Piu Chan, Michael Schwarzschild, David Simon, Cindy Zadikoff</p>	Grand Ballroom Salons ABCDEFGL
3:00 - 3:15 PM	Break	All	
3:15 – 5:00 PM	<p>HOW to measure prevention?:</p> <ul style="list-style-type: none"> Molecular Imaging Digital motor metrics Clinical outcome measures Cognitive & psychiatric endpoints Panel discussion; audience Q&A 	<p>*Tanya Simuni John Seibyl Anat Mirelman Lana Chahine Daniel Weintraub Lana Chahine, Chris Coffey, Anat Mirelman, John Seibyl, Daniel Weintraub</p>	Grand Ballroom Salons ABCDEFGL
5:00 – 5:15 PM	<p>Group photo</p> <p>Exit north entrance of Boston Marriott Long Wharf</p>	In-Person Attendees Only	Christopher Columbus Park/Boston Harborwalk
5:30 - 7:00 PM	Networking Reception	In-Person Attendees Only	Harbor View Ballroom & Terrace
5:30 - 7:00 PM	Poster Session	In-Person Attendees Only	Commonwealth Ballroom
7:00 - 9:00 PM	Faculty Dinner	Invitation Only	Grand Ballroom Salons HI

Tuesday – May 7 th			
Time	Event	Speakers	Location
7:00 - 8:00 AM	Breakfast	All	Palm Garden
8:00 - 10:00 AM	Comparison of emerging prevention trials <ul style="list-style-type: none"> • Protocols in development** <ol style="list-style-type: none"> 1. SlowSPEED 2. P2P master 3. PRISMS <p>Shared/distinct feature: Insights to enable success panel discussion</p>	*Michael Schwarzschild Sirwan Darweesh & Bas Bloem Ken Marek & Tanya Simuni Jesse Cedarbaum Bas Bloem, Jesse Cedarbaum, Sirwan Darweesh, Danna Jennings, Eric Macklin, Ken Marek, Alastair Noyce, Gennaro Pagano, Tanya Simuni	Grand Ballroom Salons ABCDEFGL
10:00 - 10:15 AM	Break	All	
10:15 - 11:40 AM	Challenges & Ethics of Recruiting ‘At-Risk’ <ul style="list-style-type: none"> • Recruitment from genetic cohorts • Recruitment from prodromal cohorts • Ethics of prevention trials <p>Panel discussion; audience Q&A</p>	*Alastair Noyce Lucy Norcliffe-Kaufmann Ethan Brown Eva Schaeffer Ethan Brown, Allen Dance, Nichte Mejia Gonzalez, Maggie Kuhl, Lucy Norcliffe-Kaufmann, Eva Schaeffer, Ruth Schneider	Grand Ballroom Salons ABCDEFGL
11:45 AM - 12:45 PM	Stakeholder Panel Discussion <i>Spanning advocacy, foundation, government, industry, regulatory, & research perspectives</i>	*Katie Kopil Jim Beck, Teresa Buracchio, Sophie Cho, Amit Khanna, Karl Kiebertz, Soania Mathur, Pablo Sardi, Diane Stephenson, Angela Taylor	Grand Ballroom Salons ABCDEFGL
12:45 - 1:45 PM	Lunch	All	Palm Garden
1:45 - 2:45 PM	Breakout Workshops (Discussion questions in blue)		
	1. What about co-pathologies? Do co-pathologies play a role in the early phases we are envisioning for prevention trials? Which co-pathologies play a role and how can they be assessed? Do co-pathologies change the concept of prevention trials in those affected?	*Daniela Berg & Jeffrey Kordower	Grand Ballroom Salons HI

	<p>2. Impact of biology on prevention trial design</p> <p>How can evolving understanding of the biology of disease best be incorporated into clinical trial designs aimed at prevention?</p> <p>Is biological characterization of participants necessary for enrollment in PD prevention trials?</p>	*Carlie Tanner & Un Jung Kang	Grand Ballroom Salons JK
	<p>3. Outcome measures for prevention trials</p> <p>What are the most promising biomarkers or endpoints for PD prevention trials?</p> <p>Is there a role for wet biomarkers for disease progression?</p> <p>In a biologically defined disease with variable phenotypic presentations, how can outcome measures be defined?</p>	*Tanya Simuni & Karl Kieburz	Quincy/ Haymarket
	<p>4. At risk perspectives of prevention trials</p> <p>What unique ethical concerns must be addressed to recruit and retain at-risk individuals into PD prevention trials?</p> <p>How can at-risk individuals with different concerns best work together to ensure success of all PD prevention trials?</p>	*Jessi Keavney & Soania Mathur	Beacon/Faneuil
3:00 - 3:30 PM	Debrief of workshops & consensus on progress and next steps	*Grace Crotty Daniela Berg, Carlie Tanner, Tanya Simuni, Jessi Keavney	Grand Ballroom Salons ABCDEFGL
3:30 PM	Adjourn		

*moderator

**Study/platform acronyms: [P2P](#) = Path-to-Prevention (Trial), PRISMS = An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD), SlowSPEED = Slowing Parkinson's Early through Exercise Dosage

Please note that this is a draft agenda and is subject to change.